Cwm LLC Has $239,000 Holdings in Kura Oncology, Inc. $KURA

Cwm LLC lifted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 46.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,406 shares of the company’s stock after purchasing an additional 13,053 shares during the period. Cwm LLC’s holdings in Kura Oncology were worth $239,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of KURA. State of Wyoming acquired a new stake in Kura Oncology in the first quarter worth $48,000. Pallas Capital Advisors LLC raised its holdings in Kura Oncology by 32.2% in the second quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after purchasing an additional 3,241 shares during the period. Magnetar Financial LLC acquired a new stake in Kura Oncology in the first quarter worth $79,000. E Fund Management Co. Ltd. raised its holdings in Kura Oncology by 18.9% in the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company’s stock worth $81,000 after purchasing an additional 1,951 shares during the period. Finally, KLP Kapitalforvaltning AS raised its holdings in Kura Oncology by 179.4% in the second quarter. KLP Kapitalforvaltning AS now owns 19,000 shares of the company’s stock worth $110,000 after purchasing an additional 12,200 shares during the period.

Kura Oncology Stock Up 13.8%

Shares of KURA opened at $11.04 on Tuesday. The company has a market cap of $958.27 million, a PE ratio of -4.88 and a beta of 0.32. The business has a fifty day moving average of $8.75 and a 200 day moving average of $7.07. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $19.73. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analysts’ expectations of $64.95 million. On average, sell-side analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Guggenheim began coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They issued a “neutral” rating for the company. Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Zacks Research cut shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 7th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Insider Transactions at Kura Oncology

In related news, insider Teresa Brophy Bair sold 8,805 shares of Kura Oncology stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $78,716.70. Following the sale, the insider owned 148,043 shares of the company’s stock, valued at approximately $1,323,504.42. This trade represents a 5.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 12,314 shares of the stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $110,087.16. Following the completion of the transaction, the insider directly owned 158,439 shares of the company’s stock, valued at approximately $1,416,444.66. This represents a 7.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 78,058 shares of company stock valued at $697,839 over the last quarter. Company insiders own 6.40% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.